March 27, 2019
Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating GPRC5D as a Promising Target for Antibody-Based Therapies in Multiple Myeloma
Potential to target GPRC5D in multiple myeloma patients relapsed after BCMA-targeted therapy EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage…